Salpingo-Oophorectomy Overview

Save information for later
Sign Up

Learn About Salpingo-Oophorectomy

Who are the top Salpingo-Oophorectomy Local Doctors?
Steven A. Narod
Elite in Salpingo-Oophorectomy
Elite in Salpingo-Oophorectomy
790 Bay Street, 
Toronto, ON, CA 

Steven Narod practices in Toronto, Canada. Mr. Narod and is rated as an Elite expert by MediFind in Oophorectomy. His top areas of expertise are Ovarian Cancer, Breast Cancer, BRCA Positive Breast Cancer, Oophorectomy, and Mastectomy.

Joanne Kotsopoulos
Elite in Salpingo-Oophorectomy
Elite in Salpingo-Oophorectomy
76 Grenville St, 
Toronto, ON, CA 

Joanne Kotsopoulos practices in Toronto, Canada. Ms. Kotsopoulos and is rated as an Elite expert by MediFind in Oophorectomy. Her top areas of expertise are BRCA Positive Breast Cancer, Ovarian Cancer, Breast Cancer, Oophorectomy, and Salpingo-Oophorectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Philippe Morice
Elite in Salpingo-Oophorectomy
Elite in Salpingo-Oophorectomy

Gustave Roussy

Villejuif, FR 

Philippe Morice practices in Villejuif, France. Mr. Morice and is rated as an Elite expert by MediFind in Oophorectomy. His top areas of expertise are Cervical Cancer, Ovarian Cancer, Vaginal Cancer, Hysterectomy, and Lymphadenectomy.

What are the latest Salpingo-Oophorectomy Clinical Trials?
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

Summary: This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node+ Early Breast Cancer With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)

Summary: Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.